Dermatitis Market Growth Analysis, Trends, Size, Share, and Outlook Report 2024-2033: Strategic Insights

The dermatitis market size has grown strongly in recent years. It will grow from $6.43 billion in 2023 to $6.79 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increased prevalence, diagnostic advancements, treatment options, regulatory approvals.

The dermatitis market size is expected to see strong growth in the next few years. It will grow to $8.37 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growing patient awareness, environmental factors. Major trends in the forecast period include research and development, telemedicine and digital health, biologics and targeted therapies, personalized medicine.

Market Overview -
Dermatitis refers to the inhibitors that treat skin inflammation, which is characterized by itchy rashes on swollen and reddish skin in the outer layer of the body. It is a general term that describes a common skin irritation.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=2413&type=smp

Dermatitis Market Growth Fueled By Increasing Disease Prevalence And Food Allergies
Growth in the dermatitis market is primarily driven by the increasing global prevalence of the disease. The prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for medicines to cure this disease. For instance, in October 2022, according to the Global Atopic Dermatitis Atlas (GADA), a report published by the International Eczema Council (IEC), a US-based international dermatology association, approximately 223 million individuals were reported to be affected by atopic dermatitis in 2022. Out of this total, around 43 million were in the age group of 1 to 4 years.

Competitive Landscape -
Major companies operating in the dermatitis market include LEO Pharma AS, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer AG, Encore Dermatology Inc., Meda Pharmaceuticals Inc., Allergan Plc, Bristol-Myers Squibb Co., Anacor Pharmaceutical Inc., Astellas Pharma Inc., Mylan N.V., Valeant Pharmaceutical Inc., Galderma SA, Dow Inc., Connetics Corporation, Fujisawa Pharmaceutical Company Ltd., AbbVie Inc., F. Hoffmann-La Roche Ltd., Valeant Pharmaceuticals International Inc,, GlaxoSmithKline plc, Medimmune Inc., Bausch Health Co. Inc., Nestlé Skin Health India Pvt. Ltd., Aqua Pharmaceuticals Pvt. Ltd., C.H. Boehringer Sohn AG & Co. KG, Biofrontera AG, Zydus Lifesciences Limited

Expanding Dermatitis Market Through Strategic Mergers And Acquisitions
The dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolios and improve their market presence. Companies are also strategically making M&As to reduce competition and increase the scalability of their businesses. For instance, in March 2022, Pfizer Inc., a US-based pharmaceutical manufacturing company, acquired Arena Pharmaceuticals, Inc. for an undisclosed amount. With this acquisition, Pfizer aims to strengthen its portfolio of therapeutic candidates in various stages of development within the fields of gastroenterology, dermatology, and cardiology. Arena Pharmaceuticals, Inc. is a US-based clinical-stage company developing treatments for dermatology diseases such as atopic dermatitis (AD).

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Key Segments -

The dermatitis market covered in this report is segmented -
1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors
2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies
3) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases

Sub-Segements
By Route Of Application: Topical, Oral, Injectable

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

"Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps"

This release was published on openPR.